Current Research Studies

Cancer - NANT 2015-02: Phase I Study of Lorlatinib (PF-06463922), and Oral Small Molecule Inhibitor of ALK/ROS1, for Patients with Alk-Driven Relapsed or Refractory Neuroblastoma

Condition or Therapy:

Neuroblastoma

Category:

Cancer and blood disorders

What is the goal of this study?

The goal of this study is to determine if lorlatinib is more efficient on its own or in combination with chemotherapy for patients with refractory or recurrent neuroblastoma.

Who can join the study?

This study may be a good fit for children and young adults who

  • Are 1 to 90 years old and
  • Have been diagnosed with neuroblastoma

What will happen if my child takes part in this study?

You can read more about this study on clinicaltrials.gov.

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.


Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Navin Pinto